Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Quest Diagnostics (DGX) , which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, could be a great candidate to consider.When looking at the last two reports, this medical laboratory operator has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 1.75%, on average, in the last two quarte ...

Quest Diagnostics Inc. (DGX) has availed a personalized, one-on-one health coaching service on questhealth.com, through its subsidiary, Pack Health. The holistic programs focus on several key areas, including general health, weight management, chronic kidney disease, type 2 diabetes, or high cholesterol.For a more customised experience, individuals can pair their Quest lab work with their health coaching to put their diagnostic insights into action.Predicting DGX Stock Movement Following the NewsAfter the a ...

New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results with personalized coachingSECAUCUS, N.J,, Dec. 3, 2024 /PRNewswire/ -- Personalized, one-on-one health coaching is now available for purchase on questhealth.com. Made available by Pack Health®, a Quest Diagnostics (NYSE: DGX) company that provides evidence-based patient engagement services, questhealth.com's Health Coaching pairs individuals with board-certified health advisers who provide ...

A month has gone by since the last earnings report for Quest Diagnostics (DGX) . Shares have added about 2.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Quest Diagnostics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Quest Diagnostics Tops Q3 Earnings and Rev ...

Quest Diagnostics (DGX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of ...

Core Business and Growth Drivers - Quest Diagnostics' Advanced Diagnostics portfolio is driving growth, particularly in brain health with AD-Detect blood-based Alzheimer's disease testing and in women's health with prenatal and hereditary genetic testing [3] - The company is seeing robust demand for testing in genital tract infections, including several STIs [3] - In the cardio-metabolic health space, there is growing interest in biomarkers for early detection of cardiovascular and metabolic diseases, and the acquisition of Haystack Oncology has positioned the company in the high-growth area of ctDNA solid-tumor MRD testing [4] - Physician Lab Services experienced strong growth in Q3 2024 due to new customer wins, expanded business from Advanced Diagnostics utilization, and acquisitions [5] - Hospital Lab Services is growing above historical levels, supported by strong demand for reference testing [6] - The questhealthcom platform reported 40% growth in total revenues, driven by consumer-initiated testing and demand for expanded access to basic healthcare [6] Financial Performance and Market Position - Quest Diagnostics has a market capitalization of $1788 million and an earnings yield of 555%, outperforming the industry's yield of 345% [2] - The company's earnings surpassed estimates in the trailing four quarters, with an average surprise of 492% [2] - The Zacks Consensus Estimate for 2024 EPS is $889, with revenue expected to grow 58% to $979 billion [11] - The stock has increased 208% over the past year, compared to the industry's 294% growth and the S&P 500's 337% growth [1] Operational Excellence and Cost Management - Quest Diagnostics is strategically deploying automation and AI to improve quality, service, efficiency, and workforce experience [7] - The company's Invigorate program has consistently delivered 3% annual cost savings and productivity enhancements, helping to mitigate inflationary pressures [7] - The company completed the build-out of full end-to-end automation for core routine tests at its Lenexa, KS laboratory, making it the third fully automated lab in its national network [8] - Quest Diagnostics is piloting automated specimen accessioning in its Clifton lab to increase productivity and improve quality [8] Challenges and Risks - The company's long-term debt stood at $565 billion at the end of Q3 2024, with cash and cash equivalents at only $764 million [9] - COVID-19 testing revenues have declined significantly, with a nearly 85% drop last year and an expected $175 million decline in 2024, partially offsetting base business growth [10] Industry Comparison - Haemonetics (HAE) has an earnings yield of 502%, surpassing the industry's 118%, and its shares have risen 203% against the industry's 73% decline over the past year [12] - Boston Scientific (BSX) has a long-term estimated earnings growth rate of 138%, with shares rallying 643% compared to the industry's 265% gain [13] - Penumbra (PEN) has an estimated earnings growth rate of 335% for 2024, compared to the industry's 159%, with shares rising 99% against the industry's 234% growth [14]

Quest Diagnostics Inc.’s (DGX) third-quarter revenue growth can be attributed to the strong momentum in its expanding portfolio of Advanced Services. The company strategically deploys AI and automation to improve its operational quality and efficiency. Its base business volume remains robust, which is highly encouraging. However, the mounting debt burden on DGX’s balance sheet could pose challenges for its operations.In the past year, this Zacks Rank #2 (Buy) company’s shares have risen 12.7% compared with ...

Quest Diagnostics (NYSE: DGX ) is a provider of medical diagnostic services to markets across the world. Operations are focused on North America, where DGX has more than 2,000 locations. DGX has extensive coverage over the USBuildingBenjamins is a free stock picking and market commentary investment newsletter. Building Benjamins is the DBA (doing businesses as) publishing entity for Tradition Investment Management, LLC, a registered investment adviser. Benjamin Halliburton, our founder, also founded Traditi ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.In my previous Quest Diagnostics (NYSE: DGX ) article , I analyzed the company’s Q2 2024 earnings report, which produced a beat on EPS and revenue. The company did report that their base business revenue grew almostHe is the leader of the investing group ...

Revenue Performance - Net revenues for Q3 2024 increased to $2.488 billion, up from $2.295 billion in Q3 2023[123] - DIS revenues grew to $2.427 billion in Q3 2024, compared to $2.228 billion in Q3 2023[123] - Revenue per requisition increased by 3.3% in Q3 2024, reversing a 7.2% decline in Q3 2023[123] - Requisition volume rose by 5.5% in Q3 2024, compared to a 0.5% decline in Q3 2023[123] - DS revenues decreased to $61 million in Q3 2024 from $67 million in Q3 2023[123] Net Income - Net income attributable to Quest Diagnostics was $226 million in Q3 2024, slightly up from $225 million in Q3 2023[123] Acquisitions - The company completed the acquisition of LifeLabs for approximately USD $1 billion in August 2024[126] - Quest Diagnostics acquired select assets of PathAI Diagnostics for $100 million in June 2024[125] Cost Savings and Productivity - The Invigorate program aims to deliver 3% annual cost savings and productivity improvements[130] Restructuring and Integration Costs - The company incurred $45 million in pre-tax charges for restructuring and integration activities in the first nine months of 2024[131]